Exacerbations were defined using our usual symptomatic criteria from daily diary cards (Seemungal et al, AJRCCM 1998).

**Results** 42 COPD patients had a mean±SD age of 72.7±8.7 years, 64% male, 17% current smokers, median(IQR) 46 (19.71) pack years, mean±SD stable FEV1 1.22±0.64L and 50.7±21.5% predicted, BMI 27.7±7.4kg/m2. 13 (31%) patients had a diagnosis of GORD, of whom 12 (92%) were taking regular acid suppression therapy. There was a median (IQR) interval of 141(80,233) days between the stable and exacerbation visits.

Although median (IQR) FSSG and HARQ scores were higher at exacerbation compared to the stable state, this was not statistically significant due to high variability (6.5 (4.0,13.0) vs 5.0 (1.5,11.5), p=0.247 and 15.5 (9.0,23) vs 18.5 (11.5,24.5), p=0.096 respectively).

16/42 (38%) patients had a high FSSG score (≥8) in the stable state compared with 20/42 (48%) at exacerbation (p=0.378). 10/42 (24%) changed from a low stable FSSG to a high score at exacerbation.

27/42 (64%) patients had a high HARQ score (≥13) in the stable state compared with 30/42 (71%) at exacerbation (p=0.483). 7/42 (17%) changed from a low stable HARQ to a high score at exacerbation.

**Conclusions** GORD symptom scores are not significantly higher during acute COPD exacerbations. Due to high variability, approximately one fifth of COPD patients had a low GORD symptom score when stable and high scores at exacerbation implicating worsening reflux in some exacerbations. Further work is required to understand the potential mechanisms.

**Abstract P214 Figure 1**

**P215 LEFT VENTRICULAR HYPERTROPHY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITHOUT HYPOXAEemia: THE ELEPHANT IN THE ROOM?**

WJ Anderson, BJ Lipworth, S Rekhraj, AD Struthers, J George. University of Dundee, Dundee, United Kingdom

**Background** Chronic obstructive pulmonary disease (COPD) is associated with significant cardiovascular mortality. Left ventricular hypertrophy (LVH) is a pivotal cardiovascular risk factor. The prevalence of LVH in COPD is currently unknown.

**Methods** We performed a pilot study of 93 normoaxaemic COPD patients and 34 controls. Patients underwent echocardiography to measure left ventricular (LV) dimensions; electrocardiography; 24-hour blood pressure (BP) recording; and serum B-type natriuretic peptide (BNP) levels, along with spirometry and oxygen saturations.

**Results** COPD patients’ oxygen saturations were normal at 96.5% (95%CI: 96.1–97.0%), with a mean FEV1 of 70.0% predicted (95% CI: 65.2–74.8%). 30.1% of COPD patients met echocardiographic criteria for LVH based on LV mass index, with more LVH in females than males (43.2% vs. 21.4%, p=0.02). LV mass index in COPD was 96.2g/m2 (95%CI: 90.1–102.7g/m2) vs. controls 82.9g/m2 (95%CI: 75.8–90.6g/m2), p=0.017 (Figure 1). LV mass index remained high in COPD patients in the absence of hypertension history (94.5g/m2 vs. 79.9g/m2, p=0.015) and with 24-hr systolic BP<135mmHg (96.7g/m2 vs. 82.5g/m2, p=0.024). LV ejection fraction (mean=63.4%) and BNP (mean=28.7pg/ml) were normal in COPD patients. Mean 24hr BP was normal in COPD patients at 125/72mmHg. Electrocardiography was less sensitive for detecting LVH than echocardiography.

**Conclusion** LVH was present in a significant proportion of normotensive, normoxaemic COPD patients, especially in females, along with normal LV ejection fraction and BNP levels. Clinical trials are therefore indicated to evaluate treatments to regress LVH in patients with COPD.

![Figure 1](http://example.com/figure1.png)